TWO · 7729.TWO
Steminent Biotherapeutics Inc.
NT$177.00+NT$2.50 (+1.43%)
Steminent Biotherapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.25% below the high.
Loading market information…
TWO · 6461.TWO · TWD
Stock price
Quote as of Oct 30, 2026, 05:24 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Intech Biopharm Corporation’s quoted price sits in the lower half of its reported 52-week range, 36.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Intech Biopharm Corporation is a pharmaceutical company dedicated to the global development and production of generic medications for respiratory conditions. Their portfolio includes innovative drug delivery systems, such as iLEF (inhaled low ethanol formulation), a proprietary metered dose inhaler platform specifically engineered for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Additionally, they offer a dry powder inhaler (DPI) technology, which utilizes blisters and capsules for precise dosage. These therapeutic solutions are marketed under various brand names, including SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011. Established in Taipei, Taiwan, in 2010, the company maintains its headquarters in the city.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
NT$177.00+NT$2.50 (+1.43%)
Steminent Biotherapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.25% below the high.
NT$155.00NT$0.00 (0.0%)
Hcmed’s quoted price sits in the upper half of its reported 52-week range, 11.43% below the high.
NT$54.00-NT$1.70 (-3.05%)
Sinew Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.47% below the high.
NT$26.40-NT$0.40 (-1.49%)
Taiwan Bio Therapeutics Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 19.76% below the high.
NT$21.30-NT$0.15 (-0.7%)
GlycoNex Incorporation’s quoted price sits in the lower half of its reported 52-week range, 29.0% below the high.
NT$43.30-NT$0.30 (-0.69%)
HeXun Biosciences Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.53% below the high.
NT$20.80-NT$0.30 (-1.42%)
Gwo Xi Stem Cell Applied Technology Co. , Ltd’s quoted price sits in the lower half of its reported 52-week range, 28.03% below the high.
NT$9.42-NT$0.25 (-2.59%)
Sunny Pharmtech Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.54% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
